MYND Life Sciences Inc. (MYNDF)
MYND Life Sciences Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Port Coquitlam, BC, CA. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $657,843. On trailing twelve-month figures it carries a trailing P/E of -2.18, a net margin of 0.0%. Its beta of 0.98 implies it has historically moved less than the broad market.
Headquartered in Kelowna, Canada, MYND Life Sciences Inc. operates as a neuro-pharmaceutical enterprise focused on creating innovative therapies for depressive disorders. The company conducts scientific research and clinical trials across Canada and the United States to develop drugs derived from neuro-anti-inflammatory compounds. A significant part of their work involves the study and development of psilocin and psilocybin extracts, as well as their synthetic analogs.
MYND Life Sciences Inc. is most often compared with the following Healthcare names: